Here are five points:
1. The new investors include Rock Springs Capital, Invesco Asset Management, Health for Life Capital and PureTech.
2. Vedanta Biosciences will use the funding for its clinical studies in infectious and autoimmune diseases.
3. The financing will also help with developing the company’s technology platform.
4. Vedanta Biosciences has already isolated human-associated bacterial strains as well as characterized how the immune system recognizes and responds to microbes.
5. The company has identified drug candidates composed of defined bacterial consortia, for infectious disease, immune tolerance, inflammation and immuno-oncology.
More articles on quality & infection control:
Former surgical tech tests HIV positive; compromises 1.5k patients: 5 key points
6 steps to create & maintain an outstanding ASC infection control program
Electronic monitoring increases hand hygiene compliance: 5 observations
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.